This retrospective study found highly significant rates of medication adherence when patients were switched from either generic valproic acid or Depakote DR to Depakote ER. Patients switched to Depakote ER did not gain a statistically significant amount of weight. Gastrointestinal (GI) complaints decreased profoundly, as well as complaints of somnolence, fatigue, and cognitive dulling. The study findings demonstrated improved compliance and diminished adverse events when patients were afforded the opportunity to take the once-a-day, enteric-coated form of divalproex, Depakote ER. The correctional system provides an opportunity to improve the functionality and quality of life of inmates who are mentally ill. Patients’ ability to tolerate medications influences their adherence to a medication regimen. Rates of nonadherence among bipolar patients are unacceptably high. In an effort to reduce treatment costs, many correctional programs are considering eliminating newer psychotropic medicines in favor of cheaper generic medications. This study identified all patients incarcerated in the Muscogee County Jail who were treated with valproic acid, Depakote DR, or the extended release form of divalproic sodium, Depakote ER. The study sought to discover if patient compliance improved when switched from valproic acid or Depakote DR to the once-a-day dose of Depakote ER. References